Literature DB >> 19394083

Upregulation of stem cell genes in multidrug resistant K562 leukemia cells.

Gustav Lehne1, Unn-Hilde Grasmo-Wendler, Jeanne-Marie Berner, Leonardo A Meza-Zepeda, Birgitte Lid Adamsen, Aksel Flack, Andrew Reiner, Ole Petter Fraas Clausen, Eivind Hovig, Ola Myklebost.   

Abstract

The transmembrane transporter P-glycoprotein (P-gp) encoded by ABCB1, is one major cause for multidrug resistance (MDR). We compared the genomic profile and gene expression pattern of the P-gp positive K562VCR cells with parental P-gp negative K562wt cells. In K562VCR array CGH revealed amplification of ABCB1, ABCB4, ABCB5 and SEMA3D, whereas expression microarrays demonstrated upregulation of stem cell genes (e.g. KIT and HOXB4), anti-apoptotic genes (e.g. IGF1R and CCNG1), and downregulation of pro-apoptotic genes (e.g. CASP4, 6 and 7). Thus, K562VCR cells disclose stem cell characteristics including a range of drug resistance mechanisms possibly attained as a stem cell program switched on en bloc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394083     DOI: 10.1016/j.leukres.2009.03.028

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Authors:  Gisela Caceres; Robert W Robey; Lubomir Sokol; Kathy L McGraw; Justine Clark; Nicholas J Lawrence; Said M Sebti; Michael Wiese; Alan F List
Journal:  Cancer Res       Date:  2012-07-03       Impact factor: 12.701

Review 2.  The therapeutic promise of the cancer stem cell concept.

Authors:  Natasha Y Frank; Tobias Schatton; Markus H Frank
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

3.  The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study.

Authors:  Hala M Farawela; Mervat M Khorshied; Neemat M Kassem; Heba A Kassem; Hamdy M Zawam
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-08       Impact factor: 4.553

4.  Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

Authors:  C P Coyne; Lakshmi Narayanan
Journal:  J Pharm Drug Deliv Res       Date:  2015-03-20

Review 5.  Identification and targeting of cancer stem cells.

Authors:  Tobias Schatton; Natasha Y Frank; Markus H Frank
Journal:  Bioessays       Date:  2009-10       Impact factor: 4.345

6.  Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms.

Authors:  Karobi Moitra; Mark Scally; Kate McGee; Germaine Lancaster; Bert Gold; Michael Dean
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

7.  Benzene Exposure Alters Expression of Enzymes Involved in Fatty Acid β-Oxidation in Male C3H/He Mice.

Authors:  Rongli Sun; Meng Cao; Juan Zhang; Wenwen Yang; Haiyan Wei; Xing Meng; Lihong Yin; Yuepu Pu
Journal:  Int J Environ Res Public Health       Date:  2016-10-31       Impact factor: 3.390

8.  Elevated expression of ABCB5 in ocular surface squamous neoplasia.

Authors:  Passara Jongkhajornpong; Takahiro Nakamura; Chie Sotozono; Maho Nagata; Tsutomu Inatomi; Shigeru Kinoshita
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

9.  Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Drug Des Devel Ther       Date:  2016-08-12       Impact factor: 4.162

10.  Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance.

Authors:  Anna Vert; Jessica Castro; Marc Ribó; Maria Vilanova; Antoni Benito
Journal:  Onco Targets Ther       Date:  2018-01-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.